In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Venus Concept (VERO – Research Report). The company’s shares closed today at $0.63.
According to TipRanks, Vendetti is an analyst with an average return of -6.2% and a 32.80% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Lucid Diagnostics, Nuwellis, and Biolase.
Venus Concept has an analyst consensus of Hold.
The company has a one-year high of $2.92 and a one-year low of $0.60. Currently, Venus Concept has an average volume of 575K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Venus Concept (VERO) Company Description:
Venus Concept, Inc. is a medical aesthetic technology company. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded in 2002 and is headquartered in Toronto, Canada.
Read More on VERO:
- Venus Concept reports Q1 EPS ($1.68), consensus ($1.53)
- Venus Concept announces loan purchase, completes of 1st phase of refinance
- Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
- Venus Concept files to sell 1.64M shares of common stock for holders
- Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
